NO20001437D0 - Kombinasjonsterapi for å utrydde detekterbart HCV-RNA hos pasienter med kronisk hepatitt C-infeksjon - Google Patents

Kombinasjonsterapi for å utrydde detekterbart HCV-RNA hos pasienter med kronisk hepatitt C-infeksjon

Info

Publication number
NO20001437D0
NO20001437D0 NO20001437A NO20001437A NO20001437D0 NO 20001437 D0 NO20001437 D0 NO 20001437D0 NO 20001437 A NO20001437 A NO 20001437A NO 20001437 A NO20001437 A NO 20001437A NO 20001437 D0 NO20001437 D0 NO 20001437D0
Authority
NO
Norway
Prior art keywords
infection
patients
combination therapy
chronic hepatitis
hcv rna
Prior art date
Application number
NO20001437A
Other languages
English (en)
Norwegian (no)
Other versions
NO20001437L (no
Inventor
Janice K Albrecht
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27130070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20001437(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/938,033 external-priority patent/US6172046B1/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20001437L publication Critical patent/NO20001437L/no
Publication of NO20001437D0 publication Critical patent/NO20001437D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20001437A 1997-09-21 2000-03-20 Kombinasjonsterapi for å utrydde detekterbart HCV-RNA hos pasienter med kronisk hepatitt C-infeksjon NO20001437D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/938,033 US6172046B1 (en) 1997-09-21 1997-09-21 Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US93512397A 1997-09-22 1997-09-22
PCT/US1998/018488 WO1999015194A1 (fr) 1997-09-21 1998-09-16 Traitement associe pour eradiquer le vhc-arn decelable chez des patients atteints d'hepatite c chronique

Publications (2)

Publication Number Publication Date
NO20001437L NO20001437L (no) 2000-03-20
NO20001437D0 true NO20001437D0 (no) 2000-03-20

Family

ID=27130070

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001437A NO20001437D0 (no) 1997-09-21 2000-03-20 Kombinasjonsterapi for å utrydde detekterbart HCV-RNA hos pasienter med kronisk hepatitt C-infeksjon

Country Status (24)

Country Link
EP (3) EP0903148B1 (fr)
JP (1) JPH11152231A (fr)
KR (1) KR20010024188A (fr)
CN (1) CN1250283C (fr)
AR (1) AR013497A1 (fr)
AT (2) ATE206618T1 (fr)
AU (1) AU749924B2 (fr)
BR (1) BR9812484A (fr)
CA (1) CA2245938C (fr)
CO (1) CO4970691A1 (fr)
DE (2) DE69810822T2 (fr)
DK (2) DK1136075T3 (fr)
ES (2) ES2186660T3 (fr)
HK (2) HK1016505A1 (fr)
HU (1) HUP0100092A3 (fr)
IL (1) IL134428A0 (fr)
MY (1) MY117781A (fr)
NO (1) NO20001437D0 (fr)
NZ (1) NZ502740A (fr)
PE (1) PE119199A1 (fr)
PT (1) PT903148E (fr)
SK (1) SK3922000A3 (fr)
TW (1) TW568787B (fr)
WO (1) WO1999015194A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2172288T3 (es) * 1998-05-15 2002-09-16 Schering Corp Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c.
WO2000037110A2 (fr) * 1998-12-18 2000-06-29 Schering Corporation Traitement du vhc par induction d'interferon-alpha pegyle combine la ribavirine
AR022116A1 (es) * 1998-12-18 2002-09-04 Schering Corp Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
DE19919585A1 (de) 1999-04-29 2000-12-07 Cmi Ag Verwendung von Phyllanthus zur Behandlung von oxidativem Streß und anderen Symptomen
EP1276849A4 (fr) 2000-04-12 2004-06-09 Human Genome Sciences Inc Proteines fusionnees a de l'albumine
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1736478B1 (fr) 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Procédés et compositions de traitement des flavivirus et des pestivirus
US7208167B2 (en) 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
US7053228B2 (en) 2000-09-18 2006-05-30 Applied Research Systems Ars Holding N.V. Sulfur analogues of 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) for treating excess of glucocorticoids
DK1463751T3 (da) 2001-12-21 2013-08-26 Human Genome Sciences Inc Albuminfusionsproteiner.
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US7456155B2 (en) 2002-06-28 2008-11-25 Idenix Pharmaceuticals, Inc. 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
AP2005003212A0 (en) 2002-06-28 2005-03-31 Centre Nat Rech Scient Modified 2' and 3' nucleoside prodrugs for treating flaviviridae infections.
JP2004155777A (ja) * 2002-10-16 2004-06-03 Asahi Kasei Pharma Kk Ｃ型慢性肝炎治療剤
DK1576138T3 (en) 2002-11-15 2017-05-01 Idenix Pharmaceuticals Llc 2'-METHYL NUCLEOSIDES IN COMBINATION WITH INTERFERON AND FLAVIVIRIDAE MUTATION
CA2527657C (fr) 2003-05-30 2011-06-14 Pharmasset, Inc. Analogues de nucleosides fluores modifies
BRPI0413474A (pt) * 2003-08-13 2006-10-17 Smith Howard J & Ass Pty Ltd uso de interferon e ribavirina e kit para uso no tratamento de infecções virais
ES2245248B1 (es) * 2004-06-09 2007-02-16 Universidad De Salamanca Uso de la artemisinina y sus derivados en la fabricacion de medicamentos utiles como agentes antiviricos.
SG158136A1 (en) 2004-09-14 2010-01-29 Pharmasset Inc Preparation of 2`-fluoro-2`- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2009015336A2 (fr) 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Produits médicamenteux d'interféron à libération régulée et traitement d'une infection par hcv utilisant ceux-ci
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
MX2011006891A (es) 2008-12-23 2011-10-06 Pharmasset Inc Fosforamidatos de nucleosidos.
AR074882A1 (es) 2008-12-23 2011-02-16 Pharmasset Inc Analogos de nucleosidos
JP5793084B2 (ja) 2008-12-23 2015-10-14 ギリアド ファーマセット エルエルシー プリンヌクレオシドの合成
JP2012526149A (ja) 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
PE20130151A1 (es) 2010-03-31 2013-02-21 Gilead Pharmasset Llc Sintesis estereoselectiva de activos que contienen fosforo
ES2716158T3 (es) 2010-11-30 2019-06-10 Gilead Pharmasset Llc 2'-spiro-nucleótidos para el tratamiento de hepatitis C
CN106166160A (zh) 2011-09-16 2016-11-30 吉利德制药有限责任公司 用于治疗hcv的组合物
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SE1450019A1 (sv) 2011-10-21 2014-01-10 Abbvie Inc Förfaranden för att behandla HCV innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
SG10201706949VA (en) 2013-01-31 2017-09-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
NZ716840A (en) 2013-08-27 2017-06-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
WO2015136455A1 (fr) * 2014-03-13 2015-09-17 Novartis Ag Nouveaux traitements d'une infection par le virus de l'hépatite c
CA3022119A1 (fr) 2016-04-28 2017-11-02 Emory University Compositions therapeutiques a base de nucleotides et nucleosides contenant un alcyne et utilisations associees

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection

Also Published As

Publication number Publication date
NO20001437L (no) 2000-03-20
DE69801970T2 (de) 2002-06-13
ES2186660T3 (es) 2003-05-16
EP1317929A3 (fr) 2003-07-02
ES2162393T3 (es) 2001-12-16
AU9473798A (en) 1999-04-12
CA2245938A1 (fr) 1999-03-21
HUP0100092A2 (hu) 2001-05-28
DE69801970D1 (de) 2001-11-15
CN1250283C (zh) 2006-04-12
CA2245938C (fr) 2003-07-15
ATE206618T1 (de) 2001-10-15
SK3922000A3 (en) 2000-10-09
DK0903148T3 (da) 2001-12-17
AU749924B2 (en) 2002-07-04
ATE230999T1 (de) 2003-02-15
JPH11152231A (ja) 1999-06-08
DE69810822T2 (de) 2003-11-20
PT903148E (pt) 2002-02-28
EP1136075B1 (fr) 2003-01-15
EP0903148A3 (fr) 1999-04-28
PE119199A1 (es) 1999-12-01
CN1271292A (zh) 2000-10-25
AR013497A1 (es) 2000-12-27
IL134428A0 (en) 2001-04-30
CO4970691A1 (es) 2000-11-07
HUP0100092A3 (en) 2002-03-28
EP1317929A2 (fr) 2003-06-11
EP0903148A2 (fr) 1999-03-24
KR20010024188A (ko) 2001-03-26
TW568787B (en) 2004-01-01
EP0903148B1 (fr) 2001-10-10
HK1041440B (zh) 2003-09-05
DE69810822D1 (de) 2003-02-20
DK1136075T3 (da) 2003-04-28
MY117781A (en) 2004-08-30
EP1136075A1 (fr) 2001-09-26
BR9812484A (pt) 2000-09-19
NZ502740A (en) 2002-10-25
HK1041440A1 (en) 2002-07-12
WO1999015194A1 (fr) 1999-04-01
HK1016505A1 (en) 1999-11-05

Similar Documents

Publication Publication Date Title
NO20001437D0 (no) Kombinasjonsterapi for å utrydde detekterbart HCV-RNA hos pasienter med kronisk hepatitt C-infeksjon
ZA988466B (en) Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
NO20005755L (no) Kombinasjonsterapi omfattende ribavirin og interferon-<alfa> hos antivirusbehandlingsnaive pasienter med kronisk hepatitt C- infeksjon
WO2000037110A3 (fr) Traitement du vhc par induction d'interferon-alpha pegyle combine la ribavirine
BR0114636A (pt) Terapia combinada para hcv de interferon-alfa peguilado/ribavirina
AU2001255495A1 (en) Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection
IL139786A0 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
NO20015059D0 (no) HCV-kombinasjonsterapi, inneholdende ribavirin i assosiasjon med antioksydanter
EP0707855A3 (fr) Thérapie combinée contre une infection de l'hépatite C chronique
NO20011789L (no) Ribavirin-interferon <alfa> kombinasjonsterapi for utryddelse av påvisbar HCV-RNA i pasienter med kronisk hepatitt C-infeksjon
IL162236A0 (en) Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use
DK0669123T3 (da) Infusionsbeholder med to tilslutninger
PL363175A1 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
ID24720A (id) Senyawa amidino tersubstitusi dalam perawatan penyakit gangguan paru-paru kronis
ECSP993178A (es) Terapia combinatoria con ribarvirina -interferon alfa para erradicar el hcv - rna detectable en aquellos pacientes que presentan infeccion por hepatitis c cronica
ATE251855T1 (de) Herrenunterhose mit schutzstruktur

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application